Management of High‑Probability Pulmonary Embolism (Wells Score 7)

Immediate Anticoagulation

• Initiate therapeutic anticoagulation as soon as PE is suspected; do not wait for imaging when clinical probability is high. 1
• For hemodynamically stable patients (SBP ≥ 90 mmHg, no shock), give low‑molecular‑weight heparin (LMWH) or fondaparinux rather than unfractionated heparin. 2
• LMWH should be dosed weight‑based (e.g., enoxaparin 1 mg/kg SC every 12 h). 3
• For hemodynamically unstable patients (SBP < 90 mmHg, shock), use unfractionated heparin with a weight‑adjusted bolus (≈ 80 U/kg IV) followed by continuous infusion (≈ 18 U/kg/h) targeting an aPTT 1.5–2.5 × control. 3

Diagnostic Imaging

• CT pulmonary angiography (CTPA) is the first‑line imaging test; it should be performed within 1 hour for suspected high‑risk PE and within 24 hours for non‑massive PE. 4
• When transport is unsafe for unstable patients, perform bedside echocardiography to look for right‑ventricular dysfunction and confirm high‑risk PE. 1

Risk Stratification & Definitive Treatment

High‑Risk (Hemodynamically Unstable) PE

• Systemic thrombolysis is the first‑line therapy unless absolutely contraindicated. 2
• Alteplase 100 mg IV over 90 min is recommended for stable patients; a 50 mg IV bolus may be used during cardiac arrest. 5
• If thrombolysis is contraindicated or fails, consider surgical pulmonary embolectomy. 2
• Provide supportive care (oxygen for hypoxemia; norepinephrine or dobutamine for hypotension). 3
• Avoid aggressive fluid boluses, which can worsen right‑ventricular failure. 3

Intermediate‑Risk (Hemodynamically Stable with RV Dysfunction) PE

• Anticoagulation alone is the standard initial treatment; routine thrombolysis is not recommended. 2
• Reserve rescue thrombolysis for patients who develop hemodynamic deterioration. 2
• Ensure close monitoring in an appropriate care setting. 1

Low‑Risk (Hemodynamically Stable, No RV Dysfunction) PE

• Anticoagulation alone suffices; early discharge and outpatient management are acceptable when no medical or social contraindications exist. 2

Anticoagulation Selection & Duration

• Direct oral anticoagulants (DOACs/NOACs) are preferred over warfarin for eligible patients (e.g., apixaban, rivaroxaban, edoxaban, dabigatran). 1
• DOACs should not be used in severe renal impairment, pregnancy/lactation, antiphospholipid antibody syndrome, or mechanical heart valves (the latter specifically cited). [2][4]
• If DOACs are contraindicated, use warfarin overlapped with parenteral anticoagulation, targeting an INR of 2.5 (range 2.0–3.0). [2][3]4
• Continue parenteral anticoagulation for at least 5 days and until INR ≥ 2.0 on two consecutive days. 3

Duration According to Etiology

Special Considerations

• Inferior vena cava (IVC) filters are reserved for absolute contraindication to anticoagulation or recurrent PE despite therapeutic anticoagulation (the latter cited). Routine filter use is not recommended. [2][5]
• Follow‑up: All PE patients require scheduled follow‑up. At 3–6 months assess persistent dyspnea/functional limitation (screen for chronic thromboembolic pulmonary hypertension) and VTE recurrence; also evaluate for occult malignancy in unprovoked cases. Yearly visits are advised for patients on extended anticoagulation. [1][2]4

Common Pitfalls to Avoid

• Do not delay anticoagulation while awaiting imaging in high‑probability patients. [1][4]
• Do not give aggressive fluid boluses to hypotensive PE patients; this worsens RV failure. 3
• Do not routinely thrombolyse intermediate‑risk PE; reserve thrombolysis for hemodynamic decline. 2
• Do not rely on D‑dimer testing to exclude PE in high‑clinical‑probability settings, as it delays treatment and is unsafe. [2][4]
• Do not prescribe NOACs in severe renal impairment, pregnancy, or antiphospholipid syndrome. 2

Management of Pulmonary Embolism

Risk Stratification and Treatment

• The European Society of Cardiology recommends immediate anticoagulation in all patients with suspected pulmonary embolism (PE) while diagnostic workup proceeds, with treatment stratified by hemodynamic stability: high-risk PE requires systemic thrombolysis, while intermediate- and low-risk PE are managed with anticoagulation alone, preferably using non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists in eligible patients 6, 7.
• High-risk PE is characterized by the presence of shock or persistent hypotension, and requires systemic thrombolytic therapy as the first-line treatment, unless absolutely contraindicated, with a Class I, Level B recommendation from the 2019 ESC guidelines 6, 7.
• Intermediate-risk PE is hemodynamically stable but with evidence of right ventricular dysfunction and/or myocardial injury, and routine use of primary systemic thrombolysis is not recommended, but rescue thrombolytic therapy is recommended if hemodynamic deterioration occurs on anticoagulation (Class I, Level B) 6, 7, 8.
• Low-risk PE is hemodynamically stable without right ventricular dysfunction or myocardial injury, and anticoagulation should be initiated without delay, with a preference for low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH), and NOACs are recommended over vitamin K antagonists for long-term anticoagulation (Class I, Level A) 6, 7, 9.

Anticoagulation and Thrombolysis

• The European Heart Journal recommends initiating anticoagulation with LMWH or fondaparinux, and transitioning to NOACs for long-term anticoagulation, with a Class I, Level A recommendation 6, 7.
• Systemic thrombolytic therapy is recommended for high-risk PE, with alteplase 50 mg IV bolus for cardiac arrest, and alteplase 100 mg over 90 minutes for stable patients, with a Class I, Level B recommendation from the 2019 ESC guidelines 6, 7, 9, 10.
• Surgical pulmonary embolectomy is recommended for high-risk PE when thrombolysis is contraindicated or has failed, with a Class I, Level C recommendation 6, 7.

Special Considerations

• The British Thoracic Society recommends specific durations of anticoagulation, including 4-6 weeks for temporary/reversible risk factors, 3 months for first idiopathic PE, and at least 6 months for other indications, with a Level A recommendation 9, 11.
• Early discharge and home treatment should be considered for carefully selected low-risk PE patients, with a Class IIa, Level A recommendation from the European Heart Journal 6, 7, 12, 10.
• Inferior vena cava (IVC) filters should be considered in specific situations, such as acute PE with absolute contraindications to anticoagulation, or PE recurrence despite therapeutic anticoagulation, but routine use is not recommended, with a Class III, Level A recommendation from the European Heart Journal 6, 7.

Management of High‑Risk Pulmonary Embolism with Hemodynamic Instability

Immediate Recognition and Definition

• Hemodynamic instability in pulmonary embolism is defined by any of the following:

Initial Anticoagulation

• In patients with suspected high‑risk PE who are hemodynamically unstable, unfractionated heparin should be started immediately (weight‑adjusted bolus ≈ 80 U/kg followed by infusion ≈ 18 U/kg/h) without waiting for imaging confirmation. (Guideline recommendation; Class I, Level B) 14, 15, 16

Rapid Diagnostic Confirmation

• Bedside transthoracic echocardiography demonstrating right‑ventricular dysfunction is sufficient to proceed with thrombolysis when clinical pre‑test probability is high. (Guideline recommendation; Class I, Level B) 17, 18

Primary Reperfusion Therapy – Systemic Thrombolysis

• Systemic thrombolysis is the first‑line treatment for high‑risk PE. (Class I, Level B) 14, 15
• Recommended regimen: alteplase 100 mg administered intravenously over 90 minutes for hemodynamically unstable patients who are not in cardiac arrest. (Class I, Level B) 15
• Thrombolytic therapy reduces short‑term mortality (relative risk 0.61; 95 % CI 0.40‑0.94), corresponding to approximately 13 fewer deaths per 1,000 treated patients. (Evidence Level B) 15, 16
• Thrombolysis is associated with an increased risk of major bleeding and intracranial hemorrhage. (Evidence Level B) 15, 16
• Untreated hemodynamically unstable PE carries a 90‑day mortality of ~50 %, supporting aggressive thrombolytic therapy despite bleeding risks. (Evidence Level C) 16

Alternative Reperfusion Strategies

Surgical Pulmonary Embolectomy

• Indicated when systemic thrombolysis is absolutely contraindicated or has failed. (Class I, Level C) 14, 15
• Although peri‑operative mortality remains high, surgery can be life‑saving in patients unable to receive thrombolysis. (Evidence Level C) 17

Catheter‑Directed Therapies

• Consider catheter‑directed therapy when:
• Three main catheter‑based approaches:

Hemodynamic Support

• Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) may be employed as a bridge to recovery or definitive intervention in patients with refractory circulatory collapse. (Class IIa, Level B) 19

Special Situations – Empirical Thrombolysis

• Empirical thrombolysis is justified when imaging is unavailable or unsafe and the patient meets all of the following:
• Empirical thrombolysis is not endorsed for undifferentiated cardiac arrest without evidence of massive PE. (Class III, Level C) 17

Contraindications to Anticoagulation

• In the presence of absolute contraindications to anticoagulation, placement of a retrievable inferior vena cava (IVC) filter (with or without concurrent embolectomy) should be strongly considered; permanent filters are reserved for rare patients with chronic contraindications. (Class IIa, Level B) 19

Practical Recommendations – Pitfalls to Avoid

• Do not withhold systemic thrombolysis because of relative contraindications when the patient faces imminent mortality from high‑risk PE. (Class I, Level B) 15, 16

Immediate Management of Pulmonary Embolism

High‑Risk (Shock or Persistent Hypotension)

• Systemic thrombolysis is the first‑line therapy for high‑risk pulmonary embolism unless an absolute contraindication exists (European Society of Cardiology guideline) 20.
• Unfractionated heparin should be started immediately with weight‑adjusted dosing (80 U/kg IV bolus followed by 18 U/kg/h infusion) and a target aPTT of 1.5–2.5 × control (ESC) 20.
• Surgical pulmonary embolectomy is indicated when thrombolysis is contraindicated or has failed (ESC) 20.

Intermediate‑Risk (Hemodynamically Stable with Right‑Ventricular Dysfunction)

• Therapeutic anticoagulation alone is the standard treatment; routine thrombolysis is not recommended (ESC) 20.
• Low‑molecular‑weight heparin (LMWH) or fondaparinux is preferred over unfractionated heparin for initial anticoagulation (ESC) 20.
• Rescue thrombolysis should be reserved only for patients who develop hemodynamic deterioration while on anticoagulation (ESC) 20.

Low‑Risk (Stable, No Right‑Ventricular Dysfunction)

• LMWH or fondaparinux is the preferred initial anticoagulant (ESC) 20.
• Early discharge and outpatient management are acceptable when no medical or social contraindications exist (ESC) 20.

Unfractionated Heparin Dosing and Monitoring (Applicable to High‑Risk PE or Severe Renal Impairment)

• Initial UFH bolus: 80 U/kg IV (or a fixed 5,000–10,000 U dose); continuous infusion: 18 U/kg/h (ESC) 21.
• aPTT should be measured 4–6 h after initiation and the infusion adjusted according to the result (ESC) 21.

• Sub‑therapeutic anticoagulation during the first 24 h increases the risk of recurrent venous thromboembolism; weight‑based nomograms should be used to achieve therapeutic levels rapidly (ESC) 21.

UFH Dosing, Monitoring, and Transition Strategies for Hemodynamically Stable Pulmonary Embolism

UFH Initiation and Therapeutic Monitoring

aPTT‑Based Dose‑Adjustment Nomogram (European Heart Journal recommendation)

22

Situations Favoring UFH Over LMWH

Transition to Long‑Term Anticoagulation

Safety Monitoring During UFH Therapy